CSIMarket Company Name, Ticker, Customers, else..
 
Lisata Therapeutics Inc   (NASDAQ: LSTA)
 
Price: $1.8750 $0.01 0.806%
Day's High: $1.8799999952316284 Week Perf: 19.43 %
Day's Low: $ 1.73 30 Day Perf: 72.02 %
Volume (M): 81,995 52 Wk High: $ 5.07
Volume (M$): $ 0 52 Wk Avg: $2.97
Open: $1.86 52 Wk Low: $0.99



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 9
 Employees 21
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Business Description


Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development, and commercialization of therapies for solid tumors and other serious diseases. Its investigational product, certepetide, aims to improve the delivery and efficacy of anti-cancer drugs by activating a tumor-specific uptake pathway and altering the tumor microenvironment. The company is conducting clinical trials across multiple solid tumor types and has entered into a merger agreement with Kuva Labs Inc.


   Company Address: P.O. Box 173 Liberty Corner 7938 NJ
   Company Phone Number: 842-0100   Stock Exchange / Ticker: NASDAQ LSTA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APRE   -4.81%    
APVO   -20.09%    
ERAS   -1.07%    
MGNX        0.5% 
RIGL   -0.44%    
ZYME   -7.58%    
• View Complete Report
   



Clinical Study

Certepetides Potential Lisata Therapeutics and WARPNINE Insights into Enhancing Immunotherapy

Published Sat, Jul 19 2025 7:18 AM UTC

In the ever-evolving landscape of medical research, the pursuit of effective cancer treatments continues to be a beacon of hope for millions. The recent announcement from Lisata Therapeutics Inc. (NASDAQ: LSTA) and WARPNINE about the completion of the iLSTA trial enrollment marks a pivotal moment in this pursuit. With compelling preliminary data consistent with earlier precl...
Product Service News

Lisata Therapeutics and GATC Health A Strategic AI Alliance for a New Era in Drug Development,

Published Mon, Mar 10 2025 11:33 AM UTC

In a bold move to redefine the pharmaceutical industry s drug development approach, Lisata Therapeutics Inc. and GATC Health have consummated the initial phase of a strategic collaboration aimed at mitigating risks and expediting the drug development continuum. The alliance harnesses GATC s cutting-edge AI-driven, validated Multiomics Advanced Technology platform, designed t...
Clinical Study

Exploring Enhanced Outcomes The Completion of Patient Enrollment in the CENDIFOX Trial for Pancreatic, Colon, and App...

Published Tue, Dec 10 2024 1:30 PM UTC

Certepetide: Advancing Treatment Potential in Pancreatic, Colon, and Appendiceal Cancers Lisata Therapeutics Announces Completion of Enrollment in CENDIFOX Trial Lisata Therapeutics, an emerging biotechnology company dedicated to pioneering advancements in therapeutic solutions for challenging conditions, has reached a significant milestone with the completion of patient en...
Clinical Study

A Breakthrough in Cholangiocarcinoma Treatment Lisata Therapeutics Advances with BOLSTER Trial

Published Tue, Sep 17 2024 12:01 PM UTC

Lisata Therapeutics has taken a significant step forward in the fight against cholangiocarcinoma with the recent announcement that the first patient has been treated in the second-line cholangiocarcinoma cohort of the ongoing BOLSTER trial. This development comes on the heels of strong enthusiasm from investigators involved in the first-line cohort, showcasing a noteworthy m...
Clinical Study

Lisata Therapeutics Advances Cancer Treatment with Orphan Drug Designation and Clinical Trials for Certepetide and LS...

Published Thu, Sep 5 2024 12:00 PM UTC

Lisata Therapeutics: Pioneering Innovative Cancer Therapies with Promising Developments in Cholangiocarcinoma and Pancreatic Cancer Treatments In the ever-evolving landscape of oncology, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a rising player in the field of clinical-stage pharmaceuticals, has made significant strides in the realm of advanced solid tumor treatments. Recent...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 170.74
Price to Sales (Expected) -
Price to Book 2.07
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.45
Working Capital Ratio 6.64
Leverage Ratio (MRQ) 0.34
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.65 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 2.12 $
Book Value 0.91 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -696,238
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.